Sprue-like Intestinal Disease Induced by Checkpoint Inhibitor Immunotherapy

Hugh J. Freeman^1,

¹Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada

Cite this paper:
Hugh J. Freeman. Sprue-like Intestinal Disease Induced by Checkpoint Inhibitor Immunotherapy. International Journal of Celiac Disease. 2020; 8(1):28-31. doi: 10.12691/ijcd-8-1-5

Abstract

In recent years, immune checkpoint inhibitors have been increasingly used in cancer treatment with significant improvements in overall survival. A downside of these agents has been the emergence of novel intestinal diseases as reflected by development of diarrhea, sometimes severe, in at least 10%. In some, an immune-mediated enterocolitis may often develop. This may be severe, difficult to manage and result in a fatal outcome. Less well appreciated, however, are other less commonly detected forms of colitis, such as collagenous colitis, along with small bowel changes, specifically, sprue-like intestinal disease, apparently occurring as an independent inflammatory process. Taken together, these are likely to represent different pathological phenotypic expressions of treatment toxicity in the intestinal tract following management of cancer with checkpoint inhibitors.

Keywords:
celiac disease sprue-like intestinal disease enteritis enterocolitis checkpoint inhibitors advanced malignancy metastatic melanoma

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Bellabeni P, Michelin O, Weide B, Romero P, Speiser DE. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 2015; 112: 6140-6145.
[2]	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 5443-5454.
[3]	Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315: 1600-1609.
[4]	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizzi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Fincenstein F, Brahmer JR. Nivolimumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
[5]	Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-1982.
[6]	Shah R, Witt D, Asif T, et al. Ipilimumab as a cause of severe pan-colitis and colonic perforation. Cureus 2017; 9: e1182.
[7]	Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Amer J Gastroenterol 2020; 115: 202-210.
[8]	Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomized, double-blind, multicenter, phase 3 trial. Lancet Oncol 2017; 18: 611-622.
[9]	Barnes MJ, Griseri T, Johnson AM, Young W, Powrie F, Izcue A. CTLA-4 promotes Foxp induction and regulatory T-cell accumulation in the intestinal lamina propria. Mucosal Immunol 2013; 6: 324-334.
[10]	Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange G, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F. Cancer immunotherapy with anti CTLA-4 monoclonal antibododies induces an inflammatory bowel disease. J Crohns Colitis 2016; 10: 395-401.
[11]	Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induced distinct immunopathological entities. J Crohns Colitis 2017; 11: 1238-1246.
[12]	Rajha E, Chaftari P, Kamal M, Maamari J, Chaftari C, Yeung SJ. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol Rep (Oxf) 2019: 8: 25-30.
[13]	Sanders D, Webber D, Chatur N. Enteritis with immune checkpoint inhibitor use. CMAJ 2019; 191: E1106.
[14]	Baroudjian B, Lourenco N, Pages C, Chami I, Maillet M, Bertheau P, Bagot M, Gornet JM, Lebbe C, Allez M. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res 2016; 26:30-311.
[15]	Freeman HJ. Role of biopsy in diagnosis and treatment of adult celiac disease. Gastroenterol Hepatol Bed Bench 2018; 11: 191-196.
[16]	Freeman HJ. Mucosal recovery and mucosal healing in biopsy-defined adult celiac disease. International J Celiac Dis 2017; 5: 14-18.
[17]	Freeman HJ. Refractory celiac disease and sprue-like intestinal disease. World J Gastroenterol 2008; 14: 828-830.
[18]	Freeman HJ. Olmesartan enteropathy. Int J Celiac Dis 2016; 4: 24-26.
[19]	Gentile M, D’Souza A, Fujii LL, Wu TT, Murray JA. Association between Ipilimumab and celiac disease. Mayo Clin Proc 2013; 88: 414-417.
[20]	Duval L, Habes S, Chatellier T, Guerzider P, Bossard C, Masliah C, Archambeaud I, Touchefeu Y, Matysiak-Budnik T. Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: case report and review of the literature. Clin Case Rep 2019; 7: 1689-1693.
[21]	Facchinetti F, Gnetti L, Caruana P, Fornaroli F, de-Angelis GL, Sabato M, Ferri L, Cosenza A, Bordi P, Tiseo M. Widespread nivolumab-induced enteropathy in a long responder non-small-cell lung cancer patient. Clin Lung Cancer 2018; 19: e591-e596.
[22]	Arnouk J, Mathew D, Nulton E, Rachakonda V. A celiac disease phenotype after checkpoint inhibitor exposure: an example of immune dysregulation after immunotherapy. ACG Case Rep J 2019; 6: e00158.
[23]	Alsaadi D, Shah NJ, Charabaty A, Atkins MB. A case of checkpoint inhibitor-induced celiac disease. J Immunother Cancer 2019; 7: 203.